Alembic Pharmaceuticals Ltd has received tentative approval from the US Food and Drug Administration for brexpiprazole tablets in 0.25 mg, 0.5 mg, 1 mg, 2 mg, 3 mg and 4 mg strengths, according to an exchange filing.
The drug is a generic version of Otsuka Pharmaceutical Co Ltd's Rexulti tablets.
It is indicated as adjunctive therapy alongside antidepressants for the treatment of major depressive disorders and schizophrenia.
According to information from IQVIA, the drug's sales for the fiscal year that ended in December 2022 totaled about $1.6 billion.
Mumbai News: JJ Hospital Paediatrics Resident Doctors Protest, Seek HOD’s Transfer After Suicide Attempt Allegation; VIDEO
Gujarat News: Daman Cemetery Land Dispute Sparks Tension As Collector Targets 6 Muslim Communities
Alia Bhatt Pens Heartfelt Note For Ahaan Panday & Aneet Padda After Watching Saiyaara: 'Two Beautiful, Magical Stars Are Born'
Rajasthan Floods: 6 Dead In Past 24 Hours, Schools Shut As Heavy Rains Lash Multiple Districts; VIDEO
The shares of the company traded 0.7% higher at ₹515.75 on NSE, at 09:15 IST.
